Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.48) per share. This is a 29.73 percent decrease over losses of $(0.37) per share from the same period last year.
Travere Therapeutics Highlights Abstract Presentations At European Renal Association – European Dialysis and Transplant Association Congress Jun. 5-7
Travere Therapeutics (NASDAQ:TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin
